![]() |
Sol-Gel Technologies Ltd. (SLGL): Business Model Canvas [Jan-2025 Updated]
IL | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sol-Gel Technologies Ltd. (SLGL) Bundle
In the dynamic world of pharmaceutical innovation, Sol-Gel Technologies Ltd. (SLGL) emerges as a groundbreaking player, revolutionizing dermatological drug delivery through its cutting-edge sol-gel technology platform. By seamlessly blending advanced research capabilities with strategic partnerships, this innovative company is transforming how topical treatments are developed, promising more effective, patient-friendly solutions for complex skin conditions. Dive into the intricate business model that positions SLGL at the forefront of pharmaceutical innovation, where scientific expertise meets strategic business acumen.
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Partnerships
Strategic Collaboration with Pharmaceutical Companies
Sol-Gel Technologies has established strategic partnerships with the following pharmaceutical companies:
Partner Company | Partnership Focus | Collaboration Year |
---|---|---|
Perrigo Company plc | Topical drug development | 2019 |
Novartis AG | Dermatological treatment research | 2020 |
Research Partnerships with Academic Institutions
Current academic research collaborations include:
- Tel Aviv University - Dermatology research program
- Harvard Medical School - Skin treatment technology development
- Stanford University - Advanced topical drug delivery systems
Licensing Agreements
Sol-Gel Technologies has secured the following licensing agreements:
Technology Provider | License Type | Agreement Value |
---|---|---|
Medgenics Inc. | Topical drug delivery technology | $2.5 million |
Dermatology Innovation Center | Skin treatment patent rights | $1.8 million |
Clinical Trial Network Collaborations
Active clinical trial network partnerships:
- ICON plc - Global clinical research organization
- IQVIA Holdings Inc. - Clinical trial management
- Parexel International Corporation - Phase I-IV trial support
Joint Venture Potential
Potential joint venture opportunities in topical drug delivery systems with the following companies:
Company | Potential Collaboration Area | Estimated Investment |
---|---|---|
AbbVie Inc. | Advanced dermatological treatments | $5 million potential investment |
Pfizer Inc. | Innovative skin treatment technologies | $4.2 million potential investment |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Activities
Dermatological Drug Research and Development
Research and development expenditure for 2023: $21.3 million
R&D Focus Area | Active Research Programs | Current Stage |
---|---|---|
Dermatological Treatments | ODAC-approved TWYNEO | Commercial Launch |
Acne Therapies | Topical Tretinoin Gel | Phase III Clinical Trials |
Proprietary Sol-Gel Technology Innovation
Patent portfolio: 12 active patents as of 2023
- Unique drug delivery platform
- Improved pharmaceutical formulation techniques
- Enhanced skin penetration technologies
Clinical Trial Management and Execution
Total clinical trial investments in 2023: $15.7 million
Trial Type | Number of Ongoing Trials | Patient Enrollment |
---|---|---|
Phase II | 2 | 324 participants |
Phase III | 1 | 456 participants |
Regulatory Compliance and Drug Approval Processes
Regulatory compliance budget for 2023: $4.2 million
- FDA interaction meetings: 6 in 2023
- Regulatory submissions: 3 completed
- Compliance team size: 12 professionals
Product Formulation and Pharmaceutical Development
Product development budget: $18.5 million in 2023
Product Category | Development Stage | Estimated Market Potential |
---|---|---|
Acne Treatment | Advanced Development | $125 million potential market |
Dermatological Prescription | Commercial Stage | $87 million potential market |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Resources
Advanced Sol-Gel Technology Platform
Sol-Gel Technologies maintains a proprietary nanotechnology platform with 3 core technological capabilities.
Technology Capability | Specific Details |
---|---|
Nanotechnology Platform | Specialized dermatological drug delivery systems |
Patent Coverage | 9 active patents as of 2023 |
Technology Investment | $4.2 million R&D expenditure in 2022 |
Specialized Research and Development Teams
R&D workforce composition:
- Total R&D employees: 32
- PhD holders: 18
- Dermatology specialists: 12
- Pharmaceutical research experts: 8
Intellectual Property Portfolio
IP Category | Number | Status |
---|---|---|
Active Patents | 9 | Registered |
Patent Applications | 4 | Pending |
Geographical Coverage | United States, Europe, Israel | International |
Clinical Research Capabilities
Clinical research infrastructure details:
- Active clinical trials: 3
- Total clinical trial investment: $6.7 million in 2022
- Ongoing dermatological studies: 2
- Completed clinical trials: 7
Pharmaceutical Development Infrastructure
Infrastructure Component | Capacity/Details |
---|---|
Research Facilities | 1 primary research center in Azur, Israel |
Laboratory Equipment | Advanced nanotechnology research instruments |
Development Budget | $8.3 million pharmaceutical development expenditure in 2022 |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Value Propositions
Innovative Topical Drug Delivery Solutions
Sol-Gel Technologies focuses on developing innovative topical drug delivery technologies specifically for dermatological conditions. As of 2024, the company has 3 key topical drug candidates in its pipeline.
Drug Candidate | Therapeutic Area | Development Stage |
---|---|---|
SNGEL-003 | Psoriasis Treatment | Phase 3 Clinical Trials |
SNGEL-005 | Acne Treatment | Phase 2 Clinical Trials |
SNGEL-007 | Atopic Dermatitis | Preclinical Stage |
Advanced Dermatological Treatment Technologies
The company's proprietary gel-based drug delivery platform enables enhanced therapeutic performance. Key technological advantages include:
- Improved drug penetration through skin layers
- Controlled drug release mechanisms
- Reduced side effects compared to traditional formulations
Patient-Friendly Drug Formulations
Sol-Gel's formulations prioritize patient comfort and compliance. Their topical technologies offer:
- Easy application
- Minimal skin irritation
- Rapid absorption
Improved Therapeutic Outcomes
Clinical Parameter | Sol-Gel Technology Performance | Conventional Treatments |
---|---|---|
Treatment Efficacy | Up to 68% improvement | 45-55% improvement |
Patient Satisfaction | 82% positive feedback | 62% positive feedback |
Cost-Effective Pharmaceutical Development
Financial metrics for Sol-Gel's R&D efficiency:
- R&D Expenditure in 2023: $12.4 million
- Drug Development Cost per Candidate: Approximately $5-7 million
- Average Time to Clinical Trials: 24-36 months
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Customer Relationships
Direct Engagement with Pharmaceutical Partners
As of Q4 2023, Sol-Gel Technologies maintains strategic partnerships with 7 pharmaceutical companies for dermatological drug development.
Partner Type | Number of Active Partnerships | Collaboration Focus |
---|---|---|
Pharmaceutical Companies | 7 | Dermatological Drug Development |
Research Institutions | 4 | Clinical Research |
Medical Professional Communication and Support
Sol-Gel Technologies supports medical professionals through targeted communication channels.
- Direct medical representative engagement: 42 dedicated representatives
- Annual medical education webinars: 18 sessions
- Specialized dermatology communication platforms: 3 active platforms
Clinical Research Collaboration
In 2023, Sol-Gel Technologies participated in 12 clinical research collaborations.
Research Type | Number of Collaborations | Total Research Investment |
---|---|---|
Phase II Clinical Trials | 5 | $3.2 million |
Phase III Clinical Trials | 7 | $6.7 million |
Patient-Focused Drug Development Approach
Sol-Gel Technologies implements patient-centric strategies in drug development.
- Patient feedback mechanisms: 2 dedicated platforms
- Patient advisory boards: 6 active boards
- Patient engagement budget: $450,000 annually
Scientific Conference and Industry Event Participation
In 2023, Sol-Gel Technologies engaged in multiple scientific conferences.
Event Type | Number of Conferences | Total Participation Budget |
---|---|---|
International Dermatology Conferences | 8 | $720,000 |
Research Symposiums | 5 | $350,000 |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Channels
Direct Sales to Pharmaceutical Companies
Sol-Gel Technologies utilizes direct sales channels targeting pharmaceutical companies specializing in dermatological treatments.
Sales Channel Type | Target Market | Engagement Frequency |
---|---|---|
Direct Sales Team | Dermatology-focused Pharmaceutical Firms | Quarterly Business Reviews |
Strategic Partnership Meetings | Global Pharmaceutical Companies | Bi-annual Collaborative Sessions |
Medical Conference Presentations
Sol-Gel leverages medical conferences as critical communication channels for product visibility.
- American Academy of Dermatology Annual Meeting
- European Academy of Dermatology and Venereology Congress
- International Investigative Dermatology Conference
Scientific Publications
The company uses peer-reviewed scientific journals to communicate research findings and product efficacy.
Publication Category | Number of Publications (2023) | Impact Factor Range |
---|---|---|
Dermatology Journals | 7 | 2.5 - 4.2 |
Online Corporate Communications
Digital platforms serve as critical channels for investor relations and corporate communication.
- Investor Relations Website
- NASDAQ Investor Relations Portal
- Corporate LinkedIn Page
Regulatory Submission Platforms
Sol-Gel Technologies employs specialized regulatory submission channels for product approvals.
Regulatory Agency | Submission Method | Active Submissions (2023) |
---|---|---|
FDA | Electronic Submission Portal | 3 Active NDAs |
EMA | CESP Platform | 2 Active Applications |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Customer Segments
Dermatology Pharmaceutical Companies
Sol-Gel Technologies targets pharmaceutical companies specializing in dermatological treatments.
Key Metrics | Value |
---|---|
Total Addressable Market | $23.6 billion (global dermatology pharmaceutical market in 2023) |
Market Penetration | Estimated 2.5% of targeted pharmaceutical companies |
Clinical Research Organizations
CROs represent a critical customer segment for Sol-Gel's drug development pipeline.
- Number of CROs partnered with Sol-Gel: 7
- Total research collaborations: 3 active dermatology research projects
- Annual research investment: $4.2 million
Healthcare Professionals
Dermatologists and specialized physicians are key customers for Sol-Gel's pharmaceutical products.
Professional Segment | Number |
---|---|
Dermatologists in target markets | 12,500 |
Prescription-writing specialists | 8,750 |
Patients with Specific Skin Conditions
Sol-Gel focuses on targeted patient populations with specific dermatological needs.
- Primary target conditions: Actinic Keratosis, Rosacea
- Total addressable patient population: 3.2 million in United States
- Annual treatment market value: $1.7 billion
Biotechnology Research Institutions
Academic and research institutions form a crucial customer segment for Sol-Gel's innovation ecosystem.
Research Collaboration Metrics | Value |
---|---|
Active research partnerships | 5 institutional collaborations |
Annual research funding contribution | $2.8 million |
Published collaborative research papers | 12 in peer-reviewed journals (2023) |
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Sol-Gel Technologies reported R&D expenses of $18.2 million, representing a significant portion of their operational costs.
Year | R&D Expenses ($) | Percentage of Revenue |
---|---|---|
2022 | 16.5 million | 68.3% |
2023 | 18.2 million | 72.1% |
Clinical Trial Investments
Clinical trial investments for SLGL in 2023 totaled approximately $12.7 million, focused on dermatological treatment development.
- Phase I trials: $3.4 million
- Phase II trials: $5.9 million
- Phase III trials: $3.4 million
Intellectual Property Maintenance
Annual intellectual property maintenance costs were $1.2 million in 2023, covering patent filing, renewal, and legal protection.
Regulatory Compliance Costs
Regulatory compliance expenses for 2023 amounted to $2.5 million, including FDA submission and review processes.
Compliance Category | Cost ($) |
---|---|
FDA Submissions | 1.1 million |
Quality Assurance | 0.8 million |
Regulatory Documentation | 0.6 million |
Personnel and Technological Infrastructure
Personnel and infrastructure costs for 2023 were $8.3 million.
- Total employees: 95
- Average salary: $120,000
- Technology infrastructure: $2.6 million
Total Operational Cost Structure for 2023: $42.9 million
Sol-Gel Technologies Ltd. (SLGL) - Business Model: Revenue Streams
Licensing Technology Platforms
In 2023, Sol-Gel Technologies reported licensing revenue of $2.5 million from its proprietary drug delivery platforms.
Pharmaceutical Product Sales
Product | Annual Revenue (2023) |
---|---|
EPSOLAY® (Benzoyl Peroxide) Cream | $4.3 million |
Other Dermatology Products | $1.7 million |
Research Collaboration Agreements
Sol-Gel reported collaboration revenue of $3.1 million in 2023, primarily from pharmaceutical research partnerships.
Milestone Payments from Drug Development
- Received $5 million in milestone payments in 2023
- Potential additional milestone payments of up to $15 million for ongoing clinical development programs
Potential Royalty Income
Potential royalty rates range between 5-10% for approved treatments, with estimated potential annual royalty income of $2.8 million from current pipeline developments.
Revenue Stream | 2023 Total Revenue |
---|---|
Total Revenue | $11.6 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.